A37 EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN’S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY

BACKGROUND: Risankizumab (RZB), an anti-IL-23 p19 inhibitor, was well-tolerated and superior to placebo (PBO) in inducing clinical remission and endoscopic response in patients (pts) with moderate-to-severe Crohn’s disease (CD) in two phase 3 studies at 12 weeks. AIMS: FORTIFY (NCT03105102), was a 5...

Descripción completa

Detalles Bibliográficos
Autores principales: Panaccione, R, Ferrante, M, Feagan, B G, Sandborn, W, Panes, J, Peyrin-Biroulet, L, Colombel, J, Schreiber, S, Dubinsky, M, Baert, F, Hisamatsu, T, Neimark, E, Huang, B, Liao, X, Song, A, Berg, S, Duan, W, Pang, Y, Pivorunas, V, Kligys, K, Wallace, K, D’Haens, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Poster of Distinction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859234/
http://dx.doi.org/10.1093/jcag/gwab049.036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859234/
http://dx.doi.org/10.1093/jcag/gwab049.036

Ejemplares similares